within Pharmacolibrary.Drugs.ATC.L;

model L01FA03
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 1.4999999999999998e-06,
    adminDuration  = 600,
    adminMass      = 1000 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0038,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0031,
    k12             = 0.52,
    k21             = 0.52
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01FA03</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Obinutuzumab is a glycoengineered humanized type II anti-CD20 monoclonal antibody used primarily in the treatment of chronic lymphocytic leukemia (CLL) and follicular lymphoma. It acts by targeting the CD20 antigen on B lymphocytes, resulting in cell lysis. Obinutuzumab is approved for clinical use in various countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adult patients with relapsed or refractory CD20-positive B-cell malignancies following intravenous administration.</p><h4>References</h4><ol><li><p>Furie, RA, et al., &amp; Malvar, A (2025). Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis. <i>The New England journal of medicine</i> 392(15) 1471–1483. DOI:<a href=&quot;https://doi.org/10.1056/NEJMoa2410965&quot;>10.1056/NEJMoa2410965</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39927615/&quot;>https://pubmed.ncbi.nlm.nih.gov/39927615</a></p></li><li><p>Zhai, J, et al., &amp; Shi, J (2017). Pharmacokinetics of obinutuzumab in Chinese patients with B-cell lymphomas. <i>British journal of clinical pharmacology</i> 83(7) 1446–1456. DOI:<a href=&quot;https://doi.org/10.1111/bcp.13232&quot;>10.1111/bcp.13232</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28072473/&quot;>https://pubmed.ncbi.nlm.nih.gov/28072473</a></p></li><li><p>Redfield, RR, et al., &amp; Borie, D (2019). Safety, pharmacokinetics, and pharmacodynamic activity of obinutuzumab, a type 2 anti-CD20 monoclonal antibody for the desensitization of candidates for renal transplant. <i>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</i> 19(11) 3035–3045. DOI:<a href=&quot;https://doi.org/10.1111/ajt.15514&quot;>10.1111/ajt.15514</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31257724/&quot;>https://pubmed.ncbi.nlm.nih.gov/31257724</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01FA03;
